Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway

Diniz, Cassiano Ricardo Alves Faria; Crestani, Ana Paula; Casarotto, Plinio Cabrera; Biojone, Caroline; Cannarozzo, Cecilia; Winkel, Frederike; Prozorov, Mikhail A.; Kot, Erik F.; Goncharuk, Sergey A.; Benette Marques, Danilo; Rakauskas Zacharias, Leonardo; Autio, Henri; Sahu, Madhusmita Priyadarshini; Borges-Assis, Anna Bárbara; Leite, João Pereira; Mineev, Konstantin S.; Castrén, Eero; Resstel, Leonardo Barbosa Moraes

doi:10.1016/j.biopsych.2024.06.021

Biological Psychiatry

2025

DOI: 10.1016/j.biopsych.2024.06.021

|View full text |Cite

Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway

Cassiano Ricardo Alves Faria Diniz,

Ana Paula Crestani,

Plinio Cabrera Casarotto

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease

Forsell,

Parrado Fernández,

Nilsson

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Neurotrophins are important regulators of neuronal and non-neuronal functions. As such, the neurotrophins and their receptors, the tropomyosin receptor kinase (Trk) family of receptor tyrosine kinases, has attracted intense research interest and their role in multiple diseases including Alzheimer’s disease has been described. Attempts to administer neurotrophins to patients have been reported, but the clinical trials have so far have been hampered by side effects or a lack of clear efficacy. Thus, much of the focus during recent years has been on identifying small molecules acting as agonists or positive allosteric modulators (PAMs) of Trk receptors. Two examples of successful discovery and development of PAMs are the TrkA-PAM E2511 and the pan-Trk PAM ACD856. E2511 has been reported to have disease-modifying effects in preclinical models, whereas ACD856 demonstrates both a symptomatic and a disease-modifying effect in preclinical models. Both molecules have reached the stage of clinical development and were reported to be safe and well tolerated in clinical phase 1 studies, albeit with different pharmacokinetic profiles. These two emerging small molecules are interesting examples of possible novel symptomatic and disease-modifying treatments that could complement the existing anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. This review aims to present the concept of positive allosteric modulators of the Trk receptors as a novel future treatment option for Alzheimer’s disease and other neurodegenerative and cognitive disorders, and the current preclinical and clinical data supporting this new concept. Preclinical data indicate dual mechanisms, not only as cognitive enhancers, but also a tentative neurorestorative function.

show abstract

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease

Forsell,

Parrado Fernández,

Nilsson

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway

Cited by 1 publication

References 67 publications

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease

Contact Info

Product

Resources

About